Additionally, JAK-inhibitor therapy has emerged as a promising therapeutic strategy to combat ARPI resistance and halt mCRPC progression [32, 33], and a phase II study is now ongoing to evaluate the effect of pacritinib (JAK2 inhibitor) in biochemically recurrent prostate cancer [34]. This evidence concerns the gene JAK2 and prostate carcinoma.